title: International experience with the CardioWest total artificial heart as a bridge to heart transplantation.
abstract: As the number of potential heart donors remains constant and the number of potential recipients continuous to increase, the need for circulatory devices to bridge patients becomes more important. The CardioWest total artificial heart (TAH) is a pneumatic, implantable system that totally replaces the failing ventricles. It has been utilized worldwide as a bridge to heart transplantation in 79 patients. There were 73 males and six females who received the TAH. Currently three patients remain on the device waiting for transplantation. A total of 55 patients (70%) were transplanted of which 50 survived (91% of patients transplanted) and were discharged home. Idiopathic/dilated cardiomyopathy was the most common etiology followed by ischemic cardiomyopathy. The mean duration of implant was 34 days (range 0-186 days) and the mean age of the group was 45 years (range 16-62 years). Twenty-one patients died while on the device. Multiple organ failure was the major cause of death. There were a total of 255 complications in this group that included reoperation, bleeding, hepatic failure, renal failure, respiratory failure, neurologic events, thromboembolic events, infections, device malfunction, and fit complications. This represented a mean complication rate of three events per patient. The survival rate for the CardioWest TAH of 91% of the patients who reached transplantation is an improvement over that of the Symbion registry (55% of those transplanted) probably as a result of a better patient selection and better control of the coagulation system. These results are also comparable to those survival results obtained with other biventricular and left ventricular assist devices currently available.
authors.affiliation: University of Arizona, Health Sciences Center, Tucson, USA.
authors.forename: F A
authors.initials: FA
authors.lastname: Arabia
authors.forename: J G
authors.initials: JG
authors.lastname: Copeland
authors.forename: R G
authors.initials: RG
authors.lastname: Smith
authors.forename: G K
authors.initials: GK
authors.lastname: Sethi
authors.forename: D A
authors.initials: DA
authors.lastname: Arzouman
authors.forename: A
authors.initials: A
authors.lastname: Pavie
authors.forename: D
authors.initials: D
authors.lastname: Duveau
authors.forename: W J
authors.initials: WJ
authors.lastname: Keon
authors.forename: R
authors.initials: R
authors.lastname: Masters
authors.forename: B
authors.initials: B
authors.lastname: Foy
authors.forename: M
authors.initials: M
authors.lastname: Carrier
authors.forename: W
authors.initials: W
authors.lastname: Dembitsky
authors.forename: J
authors.initials: J
authors.lastname: Long
authors.forename: R
authors.initials: R
authors.lastname: Kormos
mesh_terms: D000293:Adolescent; D000328:Adult; D005260:Female; D006331:Heart Diseases / Q000401:mortality / Q000503:physiopathology / Q000601:surgery*; D016027:Heart Transplantation; D006354:Heart, Artificial / Q000009:adverse effects; D006439:Hemodynamics; D006801:Humans; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D011474:Prosthesis Design; D016896:Treatment Outcome